PMV Pharma Stock

pmvpharma.comHealthcareFounded: 2013Funding to Date: $170.8MM

PMV is a biotechnology company dedicated to selectively targeting mutant p53, providing unique therapies for any patient whose tumor harbors these gene mutations.

Register for Details

For more details on financing and valuation for PMV Pharma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for PMV Pharma.

Register Today


Management Team

David Mack Ph.D
Board Member, Co-Founder, Chief Executive Officer & President
Arnold Levine Ph.D
Board Member, Co-Founder & Member of Scientific Advisory Board
Thomas Shenk Ph.D
Co-Founder & Member of the Scientific Advisory Board
Binh Vu Ph.D
Vice President of Chemistry
Winston KUng
Chief Operating Officer & Chief Financial Officer
Thomas Davis Ph.D
Vice President of Biology

Board Members

Arnold Levine Ph.D
Peter Thompson MD
Arnold Oronsky Ph.D
InterWest Partners
Steven Winick JD
Topspin Venture
David Mack Ph.D
Douglas Fisher MD
InterWest Healthcare Partners
Thilo Schroeder Ph.D
Nextech Invest

Other companies like PMV Pharma in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation


PMV Pharma Secures $62 Million in Series C Financing To Develop Cancer Drugs Targeting p53
/PRNewswire/ -- PMV Pharmaceuticals, Inc., a leader in the discovery and development of p53-targeted small molecule drugs for the treatment of cancer, today...